Skip to content

Current Research

ALZHEIMER’S DISEASE RESEARCH

 

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3)

The Alzheimer’s Disease Neuroimaging Initiative (also known as ADNI) is a historic study of brain aging looking to help change the future for this disease.

If you are 55 to 90 years of age, you may be able to help if you:

·         Are in good general health

·         Have a diagnosis of early AD, Mild Cognitive Impairment (MCI) or are cognitively normal

·         Are willing and able to undergo in-clinic assessments, memory testing and other test procedures

·         Have a study partner who can accompany you to all clinic visits

·         Are fluent in English or Spanish

This is a free study. No experimental medication will be involved.

To learn more, please visit http://www.adni3.org/  or contact Caroline Kumm at 716-558-3492 or ckumm@dentinstitute.com

 

DIZZINESS AND BALANCE RESEARCH

 

Meniere’s Disease

OTO 104-201811 – A Prospective, Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 Given as a Single Intratympanic Injection in Subjects with Unilateral Meniere’s Disease

Have you been diagnosed with Meniere’s disease? If so, you may be eligible for a clinical trial. This trial is being conducted to see if the Investigational Product helps with vertigo episodes in patients with Meniere’s disease.

To join the trial, you must meet these criteria*:

  •  Be from 18-85 years of age
  • Have been diagnosed with Meniere’s disease in one ear
  • Have had spinning (vertigo) episodes for 2 months before joining the trial
  • Have no history of middle or inner ear surgery

* Other criteria will apply.

Qualified participants will receive at no cost:

  • Investigational product of placebo (has no active ingredients) given by a one-time injection to the ear
  • Trial-related exams and follow-up
  • Education about condition

To learn more about this study, please contact Jamie So at (716) 558-3488.

Tinnitus

OTO 313-201901 –A Randomized, Double-Blind, Placebo-Controlled Phase ½ Study of OTO-313 Given as a Single Intratympanic Injection in Subjects with Subjective Tinnitus

Do you suffer from tinnitus or ringing in one ear? Are you aware of your tinnitus throughout the day?

If you answered yes to these questions and you are between 18 and 75 years old, you may qualify for a research study of an investigational product for the treatment of tinnitus.

Qualified participants will receive at no cost:

  • All trial-related examinations
  • A one time injection in the ear

To learn if you or someone you know may qualify for this clinical trial, please contact Jamie So at (716) 558-3488 or Erick Dytche at (716) 558-9929.

 

BRAIN TUMOR/ONCOLOGY RESEARCH

For information regarding brain tumor and oncology research contact Rebecca Hogan, Clinical Research Coordinator, at 716-558-5670

EPILEPSY RESEARCH 

 

Epilepsy with Partial Seizures

A0081096 – Prospective Randomized 12-Week Controlled Study of Visual Field Change in Subjects with Partial Seizures Receiving Pregabalin or Placebo.

If you have been diagnosed with Epilepsy with partial seizures and are currently taking up to three medications for its control, you may be eligible to participate in a research study evaluating an investigational medication to be added to your current therapy.

All study related visits and tests are provided at no cost for the study duration. In addition, epilepsy medications prescribed by the study doctor will be provided to you at no cost for six months after you complete the study. Reimbursement for travel and inconvenience is also provided.

For more information, please contact Jamie So at (716) 558-3488.

 

Focal Onset Epilepsy

XPF-008-201 – A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy

A clinical research study is underway for people with focal epilepsy currently taking 1-3 anti-epileptic drugs that are still experiencing frequent seizures. Three doses of investigational drug are being studied and some participants will be assigned placebo. All participants will receive active study on the extension study.

To participate in the trial, you must meet certain criteria. The following details only some of these requirements.

Study participants must:

  • Be between 18 to 75 years of age
  • Have been diagnosed with focal epilepsy at least 2 years ago
  • Be on treatment with stable dose of 1 to 3 AEDs

If you would like more information or to find out if you are eligible to participate please contact Erick Dytche at (716) 558-9929.

 

HEADACHE/MIGRAINE RESEARCH

 

Chronic Migraine

If you suffer from 15-26 headache days a month and are between 18 and 65 years of age you may qualify for exciting new research using CGRP therapy. If you are interested in participating please call 716-558-5670.

Episodic Migraine

To qualify for these trials you must be 18-65 years of age and suffer from 2-14 migraine headache days per month. The trials include both prophylactic and abortive medications. If you are interested in participating please call 716-558-5670.

Cluster Headache

To qualify for these trials you must be between 18-70 years of age and have a 1 year history of cluster headache diagnosis. If you are interested in participating please call 716-558-5670.   

MULTIPLE SCLEROSIS RESEARCH

 

INROADS: Investigational Research Study of ADS-5102 in MS Walking Impairment

The INROADS study is now enrolling volunteers to help test an investigational study drug for people with MS who have trouble walking.

You may qualify for this study if you:

·         Are 18 to 70 years of age

·         Have MS and difficulty walking

·         Have been taking a stable regimen of MS medications for at least 30 days

To learn more about this study, please contact Amanda Jamison at 716-819-4117 or ajamison@dentinstitute.com 

PASSAGE: Safety Study in Patients with Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

For this study, relapsing-remitting multiple sclerosis (RRMS) participants must be starting either Gilenya at time of study entry, starting another approved DMT, or have started a DMT within the past 6 months: Betaseron, Extavia, Avonex, Rebif, Copaxone, Aubagio and Tecfidera.

For more information, please contact Caroline Kumm at 716-558-3492.

PARKINSON’S DISEASE RESEARCH

 

PRESENCE Study: Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson’s Disease Dementia

The PRESENCE study is now enrolling volunteers to help test an investigational study drug for people with Mild-to-Moderate Parkinson’s Disease Dementia (PDD).

You may qualify for this study if you:

·         Have Mild-to-moderate Parkinson’s disease dementia

·         Are aged between 40 and 85 years old

·         Have a study partner (close friend, relative or partner) who is willing to attend certain clinic appointments with you

To learn more about this study, please visit www.thepresencestudy.com or contact Dr. Traci Aladeen at 716-558-9918.

 

INSYTE Study: Management of Parkinson’s Disease Psychosis in Actual Practice

The INSYTE study is an observational study for patients with symptoms of hallucinations and delusions associated with Parkinson’s disease. No drug is administered as part of this study and you will continue your normal medical care, including medications.

You may qualify for this study if you:

·         Are 18 and up

·         Have symptoms of hallucinations and delusions associated with Parkinson’s Disease

To learn more about this study, please contact Dr. Traci Aladeen at 716-558-9918.

RESTLESS LEG SYNDROME RESEARCH

XP109: Efficacy and Safety Evaluation of HORIZANT in Adolescents Aged 13 to 17 Years Old with Moderate-to-Severe Primary Restless Legs Syndrome

HORIZANT has been studied in adults with restless legs syndrome and is approved by the Food and Drug Administration (FDA) for adults, however it has not been approved by the FDA for teenagers. 

In this study some participants receive HORIZANT and some participants receive a placebo.

For this study you will take 2 tablets of study drug daily for 12 weeks. To find out how well HORIZANT works, 2 different doses of HORIZANT (300 mg or 600 mg) will be compared to placebo, but no one will know until the study is over which study drug a study participant was taking during the study. After completion of this trial, you can continue to the Open Label study, which means all participants receive HORIZANT.

For more information, please contact Caroline Kumm at 716-558-3492.